Use of Bone-Modifying Agents in Australian Men with Castration-Resistant Prostate Cancer (CRPC)

被引：0
|
作者：
Anton, Angelyn [1 ]
Parente, Phillip [2 ,3 ]
Azad, Arun [4 ]
Weickhardt, Andrew [5 ]
Wong, Shirley [6 ]
Shapiro, Julia [3 ]
Torres, Javier [7 ]
Parnis, Francis [8 ]
Semira, Christine [1 ]
Gibbs, Peter [1 ,6 ]
Tran, Ben [1 ,9 ]
Pezaro, Carmel [2 ,3 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Eastern Hlth, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
[6] Western Hlth, Melbourne, Vic, Australia
[7] Goulburn Valley Hlth, Melbourne, Vic, Australia
[8] Adelaide Canc Ctr, Adelaide, SA, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs100
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [31] Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)
    Mitsogiannis, Iraklis C.
    Skolarikos, Andreas
    Deliveliotis, Charalambos
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (03) : 493 - 501
  • [32] Treatment patterns by oncologists and urologists for castration-resistant prostate cancer (CRPC)
    Alemayehu, B.
    Nitz, N. M. Engel-
    Nathan, F. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
    Mashari Alzahrani
    Mark Clemons
    Marta Sienkiewicz
    Noa Shani Shrem
    Sharon F. McGee
    Lisa Vandermeer
    Sandeep Sehdev
    Marie France Savard
    Arif Awan
    Christina Canil
    Brian Hutton
    Gregory Pond
    Deanna Saunders
    Terry Ng
    Supportive Care in Cancer, 2021, 29 : 6903 - 6912
  • [34] Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
    Alzahrani, Mashari
    Clemons, Mark
    Sienkiewicz, Marta
    Shrem, Noa Shani
    McGee, Sharon F.
    Vandermeer, Lisa
    Sehdev, Sandeep
    Savard, Marie France
    Awan, Arif
    Canil, Christina
    Hutton, Brian
    Pond, Gregory
    Saunders, Deanna
    Ng, Terry
    SUPPORTIVE CARE IN CANCER, 2021, 29 (11) : 6903 - 6912
  • [35] BIOMARKERS FOR CHARACTERIZATION AND THERAPEUTIC ORIENTATION IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Plata Bello, Ana
    Tamayo Jover, Marco Antonio
    Gutierrez Nicolas, Fernando
    Acosta Lopez, Silvia
    Concepcion Masip, Tomas
    Plata Bello, Julio
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (02): : 195 - 202
  • [36] Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    Armstrong, A. J.
    George, D. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (02) : 108 - 116
  • [37] Bone-Modifying Agents: Complicated to Use
    Leng, Siyang
    Lentzsch, Suzanne
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (08) : 469 - +
  • [38] Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    D J George
    Prostate Cancer and Prostatic Diseases, 2010, 13 : 108 - 116
  • [39] Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer
    Mitchell, Aaron P.
    Nemirovsky, David
    Meza, Akriti Mishra
    Chakraborty, Nirjhar
    Persaud, Sonia
    Farooki, Azeez
    Morris, Michael J.
    JCO ONCOLOGY PRACTICE, 2024, 20 (03) : 393 - 400
  • [40] A phase I/II study of enzalutamide in combination with indomethacin in men with castration-resistant prostate cancer (CRPC)
    Leibrandt, Ryan
    Ullah, Ayman Teeham
    Verma, Rashmi
    Gao, Allen
    Lara, Primo N., Jr.
    Pan, Chong-xian
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345